Articles by K. John Morrow, Jr., PhD - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by K. John Morrow, Jr., PhD

K. John Morrow, Jr., PhD


K. John Morrow, Jr., PhD, is president of Newport Biotechnology Consultants, 625 Washington Avenue, Newport, KY 41071, kjohnmorrowjr@insightbb.com.

Articles
Angiopoietins: Novel Targets for Anti-angiogenesis Therapy
October 1, 2013

The authors review the angiopoietin pathway as an alternative for safer and more efficacious anti-angiogenic therapeutics.

Therapeutic Antibodies in Review
February 1, 2013

Innovative products and a range of indications drive the therapeutic antibody market.

Epigenetics Drives Pharma Innovation
January 1, 2013

Therapeutics targeting epigenetic mechanisms of disease will change the pharmaceutical marketplace.

Big Science Hits the Big Screen
May 1, 2011

Two films portray, in surprising detail, the hard work and determination of the biopharmaceutical industry.

Biotechs Consider Sites Outside the Industry Hubs
July 10, 2009

These are dismal times for anyone wishing to start a biotech company. The US economy and stock market are in the tank, and venture capital is tight. At least 100 of the publicly traded biotechs this year will fail or be taken over. So why would a entrepreneur want to further disadvantage himself by locating his company miles away from traditional biotech hubs like San Diego, Boston, and Rockville?

Louisiana Biotech Firm Explores the Potential of Adult Stem Cells
June 12, 2009

Nupotential, a small Louisiana biotechnology firm, believes it may have an answer to the ethical concerns and technological challenges involved in turning stem cells into medical therapies.

Louisiana Biotech Firm Explores the Potential of Adult Stem Cells
June 5, 2009

Nupotential, a small Louisiana biotechnology firm, believes it may have an answer to the ethical concerns and technological challenges involved in turning stem cells into medical therapies.

Glycosylation and the Demands of Antibody Engineering
October 1, 2007

In one series of experiments, the glycosylation site of IgG1 was removed and an IgA glycosylation site was introduced—resulting in a total loss of biological function.

SystemsX: The Final Frontier for Biotechnology?
May 23, 2007

Although difficult to conceive, the 21st century may see the boundaries of biological knowledge completely defined.

ADVERTISEMENT

ADVERTISEMENT

Click here